Thymosin Beta-4: The Parent Protein Behind TB-500 and Where the Human Data Actually Sit

Why this page exists

To read TB-500 honestly, you read thymosin beta-4 first. Thymosin beta-4 (Tβ4; gene TMSB4X; UniProt P62328) is a ubiquitous 43-amino-acid peptide, roughly 4,963 Da, that is the body's principal G-actin–sequestering molecule, present in nearly all human cells and released by platelets and macrophages at injury sites ^[5]. TB-500 is the synthetic Ac-LKKTETQ heptapeptide — residues 17–23 — its actin-binding core, near 889 Da ^[12].

The practical consequence: when a study says "thymosin beta-4 accelerated wound healing," it used the 43-residue protein, not the 7-mer sold as TB-500 ^[6]. Nearly all human data — the Phase 1 intravenous safety study and the ophthalmic RCTs — are on the full-length protein ^[6]. This page collects the parent-protein record so the how TB-500 works section can keep the fragment and the protein from being conflated.

The parent protein's established mechanism

Thymosin beta-4 binds monomeric (G-) actin one-to-one and caps both ends of the monomer, holding a buffered reserve of unpolymerized actin and regulating cytoskeletal assembly and cell motility — established at 2 Å resolution in a gelsolin-domain-1–thymosin beta-4–actin complex ^[1]. From that buffering role come its reported effects on cell migration, angiogenesis, anti-inflammatory signaling, anti-fibrotic remodeling (fewer myofibroblasts, less scarring), and progenitor-cell recruitment ^[5].

One mechanistic detail matters for honesty: full-length thymosin beta-4 can be cleaved at its N-terminus to release Ac-SDKP, a separate anti-fibrotic and angiogenic fragment — but Ac-SDKP comes from the N-terminal region and is NOT produced by the C-terminal-region TB-500 heptapeptide ^[5]. Some effects attributed loosely to "thymosin beta-4" trace to Ac-SDKP, which TB-500 cannot generate.

The animal record the parent protein carries

The reason marketing for the fragment reaches for the protein is that the protein has the strong animal data. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, raised wound contraction by at least 11% by day 7, and increased collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration two- to three-fold in vitro ^[3]. In mice, thymosin beta-4 activated the PINCH–ILK–Akt survival pathway and improved cardiac function after coronary artery ligation ^[2]. In rats with embolic stroke, intraperitoneal thymosin beta-4 improved neurological function at 2 and 12 mg/kg but not at the highest 18 mg/kg dose — a non-monotonic result with a modeled optimum near 3.75 mg/kg ^[4].

The record is honest about its limits, too. In dystrophin-deficient (mdx) mice, chronic thymosin beta-4 increased the number of regenerating fibers but did not improve muscle strength, cardiac function or fibrosis ^[5], and a porcine study found systemic thymosin beta-4 did not attenuate myocardial ischemia-reperfusion injury ^[5]. These null and negative results belong to the parent protein; the fragment has no comparable controlled series of its own ^[6].

Where the human data actually sit

The human record is full-length thymosin beta-4, and it is modest. A randomized, placebo-controlled Phase 1 study dosed synthetic thymosin beta-4 intravenously in 40 healthy volunteers at 42, 140, 420 and 1260 mg (single dose, then daily for 14 days); it was well tolerated with no dose-limiting toxicities or serious adverse events and dose-proportional pharmacokinetics ^[6]. Topical thymosin beta-4 ophthalmic solution (RGN-259) improved dry-eye signs and symptoms in a randomized, placebo-controlled trial ^[7]; a 0.1% RGN-259 formulation promoted corneal healing and integrity ^[8]; and a dry-eye program was registered on ClinicalTrials.gov ^[9]. A human acute-MI trial of thymosin beta-4 completed ^[10]; an early injectable stroke trial was withdrawn ^[11]. That is the human evidence — for the protein, not the fragment.

Thymosin beta-4 vs TB-500: the comparison table

The two are best held side by side. Thymosin beta-4 is the 43-residue parent protein (~4,963 Da) carrying nearly all the human and animal efficacy data; TB-500 is the synthetic Ac-LKKTETQ heptapeptide (~889 Da, formula C38H68N10O14) carrying the actin-binding motif but no completed controlled human trial of its own ^[6][12]. The analytical literature defined TB-500 precisely — the synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta-4 was published as a doping-control reference ^[17]. Identity is settled; standalone human efficacy of the fragment is not ^[6].

Recent parent-protein research

Thymosin beta-4 research continues on the full-length protein. A 2021 study released thymosin beta-4 from a functionalized self-assembling peptide to activate cardiac cells and promote cardiac repair, demonstrating engineered local delivery ^[16]. A 2024 study reported thymosin beta-4 improved cutaneous-flap survival in rats and activated Wnt/β-catenin signaling ^[14]. A 2026 Sports Medicine review placed thymosin beta-4/TB-500 among unapproved peptides with animal-model promise but scarce human safety data and limited regulatory oversight ^[13].